ESRRA and osteosarcoma: It was also reported that cisplatin- and doxorubicin-resistant osteosarcoma cell lines had high levels of ERRα and that targeted inhibition of ERRα by specific siRNAs or by the inverse agonist XCT-790 could restore chemosensitivity.